Other antibacterials for specialist use only (Formulary)

Use only in accordance with protocols or on advice of Microbiology, Infectious Diseases or appropriate Consultant Specialist.

COLISTIMETHATE SODIUM

Important: Therapy notes


Risk minimisation materials

Important: Formulation and dosage details

Formulation:

Injection 1 million units (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

Important: Formulation and dosage details

Formulation:

Powder for nebuliser solution 1 million units (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

Important: Formulation and dosage details

Formulation:

Dry powder for inhalation 1.66 million units/capsule (Colobreathe®) (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

DALBAVANCIN

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Powder for concentrate for solution for infusion 500mg (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

DAPTOMYCIN

Important: Therapy notes

MHRA advice: Daptomycin: risk of eosinophilic pneumonia (December 2014) (www.gov.uk).

Important: Formulation and dosage details

Formulation:

Infusion 350mg, 500mg (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

FIDAXOMICIN

Important: Therapy notes

See Clostridioides difficile guidance.

Important: Formulation and dosage details

Formulation:

Tablets 200mg (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

FOSFOMYCIN

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Oral sachets 3 grams (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

Important: Formulation and dosage details

Formulation:

Powder for solution for intravenous infusion 2 grams, 4 grams (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

LEVOFLOXACIN

Important: Therapy notes

MHRA advice: Flouroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate.  Updated safety advice is available here including a patient information leaflet.  Side effects may be disabling, long-lasting and sometimes irreversible.  Systems affected include musculoskeletal (tendonitis/rupture), neurological (muscle weakness), sensory (peripheral neuropathy) and psychiatric (tiredness, anxiety, depression and suicidal thoughts).  Fluoroquinolones should not be prescribed for self-limiting or mild to moderate infections or non-bacterial (chronic) prostatitis (January 2024).
MHRA advice: Fluoroquinolone antibiotics: suicidal thoughts and behaviour (September 2023) (www.gov.uk).  
MHRA advice: Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects (August 2023) (www.gov.uk).  

Important: Formulation and dosage details

Formulation:

Nebuliser solution 240mg (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

Dosage:

See SMC advice 1162/16.

LINEZOLID

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 600mg (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

Important: Formulation and dosage details

Formulation:

Oral suspension 100mg/5mL (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

Important: Formulation and dosage details

Formulation:

Infusion 600mg/300mL (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

RIFAXIMIN

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 550mg (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

TIGECYCLINE

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Powder for solution for infusion 50mg (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

Editorial Information

Document Id: F274